Cognitive behavioral therapy for the treatment of pediatric posttraumatic stress disorder: A review and meta-analysis

Kowalik, Joanna; Weller, Jennifer; Venter, Jacob; Drachman, David A.

doi:10.1016/j.jbtep.2011.02.002

Cited by 87 publications

(58 citation statements)

References 40 publications

(48 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The findings of randomised placebo-controlled trials in children and adolescents indicate that SSRI treatment can be effective in children and adolescents with generalised anxiety disorder, separation anxiety disorder or social anxiety disorder [I (M)] (Dieleman and Ferdinand, 2008), and also in post-traumatic stress disorder [IV] (Strawn et al, 2010), and obsessive-compulsive disorder [IV] (Gentile, 2011). Psychological treatments also have evidence of efficacy [I (M)] (Gillies et al, 2012;James et al, 2005;Kircanski et al, 2011;Kowalik et al, 2011) but the relative efficacy of pharmacological and psychological treatment approaches, alone and in combination, is not established: although combination treatment was found optimal in obsessive-compulsive disorder (March et al, 2004). In 2004, the United Kingdom Committee on Safety of Medicines stated that the balance of risks and benefits for the treatment of depressive illness in people under the age of 18 years was judged to be unfavourable for some SSRIs (escitalopram, citalopram, paroxetine and sertraline), mirtazapine and venlafaxine [IV] (Committee on Safety of Medicines, 2004), and advised caution when treating depressed adults aged 18-30 years with SSRIs.…”

Section: Children and Adolescentsmentioning

confidence: 99%

Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: A revision of the 2005 guidelines from the British Association for Psychopharmacology

et al. 2014

View full text Add to dashboard Cite

This revision of the 2005 British Association for Psychopharmacology guidelines for the evidence-based pharmacological treatment of anxiety disorders provides an update on key steps in diagnosis and clinical management, including recognition, acute treatment, longer-term treatment, combination treatment, and further approaches for patients who have not responded to first-line interventions. A consensus meeting involving international experts in anxiety disorders reviewed the main subject areas and considered the strength of supporting evidence and its clinical implications. The guidelines are based on available evidence, were constructed after extensive feedback from participants, and are presented as recommendations to aid clinical decision-making in primary, secondary and tertiary medical care. They may also serve as a source of information for patients, their carers, and medicines management and formulary committees.

show abstract

Section: Children and Adolescentsmentioning

confidence: 99%

Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: A revision of the 2005 guidelines from the British Association for Psychopharmacology

et al. 2014

View full text Add to dashboard Cite

show abstract

“…61,62 For adults, evidence-based pharmacotherapies are also available. These include benzodiazepine receptor agonist (BzRA) hypnotics (e.g., zolpidem, eszopiclone, zaleplon, temazepam, flurazepam, estazolam), doxepin, ramelteon, and suvorexant.…”

Section: Descriptionmentioning

confidence: 99%

Quality Measures for the Care of Patients with Insomnia

Edinger

Buysse

Deriy

et al. 2015

Journal of Clinical Sleep Medicine

View full text Add to dashboard Cite

The American Academy of Sleep Medicine (AASM) commissioned fi ve Workgroups to develop quality measures to optimize management and care for patients with common sleep disorders including insomnia. Following the AASM process for quality measure development, this document describes measurement methods for two desirable outcomes of therapy, improving sleep quality or satisfaction, and improving daytime function, and for four processes important to achieving these goals. To achieve the outcome of improving sleep quality or satisfaction, pre-and post-treatment assessment of sleep quality or satisfaction and providing an evidence-based treatment are recommended. To realize the outcome of improving daytime functioning, pre-and post-treatment assessment of daytime functioning, provision of an evidence-based treatment, and assessment of treatment-related side effects are recommended. All insomnia measures described in this report were developed by the Insomnia Quality Measures Workgroup and approved by the AASM Quality Measures Task Force and the AASM Board of Directors. The AASM recommends the use of these measures as part of quality improvement programs that will enhance the ability to improve care for patients with insomnia. Citation: Edinger JD, Buysse DJ, Deriy L, Germain A, Lewin DS, Ong JC, Morgenthaler TI. Quality measures for the care of patients with insomnia. J Clin Sleep Med 2015;11(3):311-334.pii: jc-00028-15 http://dx.doi.org/10.5664/jcsm.4552 I nsomnia is the most prevalent sleep disorder, and it has signifi cant consequences for health and function. Effi cacious treatments exist. However, the approach to management of insomnia is not standardized, particularly outside of sleep medicine centers. The aim of this paper is to describe the development of quality measures that can be applied to the management of insomnia patients across a wide range of ages and care settings.Insomnia is characterized by diffi culties initiating, sustaining, or obtaining qualitatively satisfying sleep despite adequate sleep opportunities and circumstances, resulting in impaired daytime functioning.1,2 Insomnia can occur across the majority of the human lifespan, from childhood years to old age. Over 33% of adults experience insomnia at least intermittently, whereas 10% to 22% suffer chronic sleep diffi culties.3-8 While prevalence data are more sparse for younger age groups, insomnia symptoms may be seen in as many as 20% to 40% children and teenagers, with slightly higher rates among girls and those with symptoms of mood disturbance. 9,10 While its signifi cance is often minimized, 11,12 persistent insomnia is associated with daytime fatigue, decreased mood, impairment in social/vocational functioning or poor school performance, and reduced quality of life.1,2,13-15 Insomnia also increases the risks for serious medical disorders, traffi c and work-site accidents, alcohol/drug abuse, and major psychiatric illnesses. 4,[16][17][18][19][20][21][22] When insomnia is comorbid with a psychiatric illness such as major depression, it c...

show abstract

“…Consistent with the adult literature, both clinical guidelines and meta-analyses identify Trauma-Focused CBT (TF-CBT) as the treatment of choice for childhood PTSD (Kowalik et al 2011;NICE 2005). It should be noted that the majority of controlled studies have focused on sexual abuse victims (e.g., Cohen et al 2004;King et al 2000).…”

Section: Introductionmentioning

confidence: 97%

A Randomized Trial of Cognitive Behaviour Therapy and Cognitive Therapy for Children with Posttraumatic Stress Disorder Following Single-Incident Trauma

Nixon

Sterk

Pearce

2011

J Abnorm Child Psychol

View full text Add to dashboard Cite

The present study compared the efficacy of trauma-focused cognitive behavior therapy (CBT) with trauma-focused cognitive therapy (without exposure; CT) for children and youth with posttraumatic stress disorder (PTSD). Children and youth who had experienced single-incident trauma (N = 33; 7-17 years old) were randomly assigned to receive 9 weeks of either CBT or CT which was administered individually to children and their parents. Intent-to-treat analyses demonstrated that both interventions significantly reduced severity of PTSD, depression, and general anxiety. At posttreatment 65% of CBT and 56% of the CT group no longer met criteria for PTSD. Treatment completers showed a better response (CBT: 91%; CT: 90%), and gains were maintained at 6-month follow-up. Maternal depressive symptoms and unhelpful trauma beliefs moderated children's outcome. It is concluded that PTSD secondary to single-incident trauma can be successfully treated with trauma-focused cognitive behavioural methods and the use of exposure is not a prerequisite for good outcome.

show abstract

Cognitive behavioral therapy for the treatment of pediatric posttraumatic stress disorder: A review and meta-analysis

Cited by 87 publications

References 40 publications

Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: A revision of the 2005 guidelines from the British Association for Psychopharmacology

Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: A revision of the 2005 guidelines from the British Association for Psychopharmacology

Quality Measures for the Care of Patients with Insomnia

A Randomized Trial of Cognitive Behaviour Therapy and Cognitive Therapy for Children with Posttraumatic Stress Disorder Following Single-Incident Trauma

Contact Info

Product

Resources

About